Clinical study of the treatment of advanced non small cell lung cancer in elderly over 70 years by gemcitabine / 中华老年医学杂志

ABSTRACT

Objective To evaluate the efficacy, toxicity and clinical benefit response of gemcitabine on advanced non small cell lung cancer in elderly. Methods Patients in the chemotherapy arm of the study received gemcitabine 1 250 mg/ m 2 as a intravenous infusion every 21 days .Patients in the best supportive care(BSC) arm should not receive chemotherapy or anticancer therapy. Results Overall survival period in the gemcitabine arm was significantly longer than in the BSC arm ( P